These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6321646)

  • 1. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A
    J Neural Transm Suppl; 1983; 19():153-61. PubMed ID: 6321646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

  • 3. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
    Brannan T; Knott P; Kaufmann H; Yahr M
    Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
    [No Abstract]   [Full Text] [Related]  

  • 6. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.
    Knoll J
    Adv Neurol; 1990; 53():425-9. PubMed ID: 2122648
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect evidence for a feedback loop mechanism between two central dopaminergic pathways: preliminary results.
    Yehuda S
    Commun Psychopharmacol; 1979; 3(2):115-9. PubMed ID: 467002
    [No Abstract]   [Full Text] [Related]  

  • 10. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 12. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
    Agid Y; Graybiel AM; Ruberg M; Hirsch E; Blin J; Dubois B; Javoy-Agid F
    Adv Neurol; 1990; 53():83-100. PubMed ID: 1978522
    [No Abstract]   [Full Text] [Related]  

  • 15. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
    Carta AR; Tronci E; Pinna A; Morelli M
    Eur J Neurosci; 2005 Mar; 21(5):1196-204. PubMed ID: 15813929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development.
    Janhunen S; Ahtee L
    Neurosci Biobehav Rev; 2007; 31(3):287-314. PubMed ID: 17141870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic intermittent L-DOPA treatment induces changes in dopamine release.
    Lundblad M; af Bjerkén S; Cenci MA; Pomerleau F; Gerhardt GA; Strömberg I
    J Neurochem; 2009 Feb; 108(4):998-1008. PubMed ID: 19196428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.